CALGARY, AB — November 17, 2025 — Leads & Copy — Seegnal Inc. (TSXV: SEGN), a global software as a service (SaaS) leader in clinical decision support solutions, has appointed Elad Bibi-Aviv, Esq. as Chief Executive Officer, effective December 16, 2025.
Bibi-Aviv brings extensive leadership experience across the AI, fintech, biotech, and health-tech industries. He has a proven track record in scaling revenue operations and driving strategic growth.
As a two-time exit entrepreneur, Bibi-Aviv has built and led high-performing teams in both startup and established ventures. From 2021 to 2022, he founded and served as CEO of Covary, an Israeli insurtech company, where he led the company to more than 10,000 customers. Following Covary’s success in the U.S. market, he played a key role in its acquisition by a U.S. insurance carrier just two years after its founding.
After the acquisition, Bibi-Aviv joined NeuroKaire, an Israeli AI-driven health-technology provider that leverages artificial intelligence and stem-cell technology to match patients with effective psychiatric medications and eliminate the trial-and-error process in prescribing. At NeuroKaire, he led the company’s operations, regulations, and sales to U.S. healthcare providers and HMOs.
Bibi-Aviv succeeds Eyal Schneid, who will continue to contribute to Seegnal as General Manager of Seegnal E-Health Ltd., the operating subsidiary of Seegnal in Israel.
Nir Dor, Chairman of Seegnal, said that the company is delighted to welcome Bibi-Aviv to Seegnal’s leadership team. Dor added that Bibi-Aviv’s experience in building AI companies and selling to healthcare providers in the U.S. positions him to lead Seegnal through its next phase of growth. Dor said that he is confident that under Bibi-Aviv’s leadership, Seegnal will accelerate its expansion and bring its life-saving platform to clinicians and pharmacists worldwide, while simultaneously delivering major cost savings to insurance carriers and HMOs by reducing unnecessary drug usage and hospitalization.
Seegnal also announced that its board of directors approved granting Bibi-Aviv stock options to purchase up to 1,359,571 common shares in the company’s capital. The options are exercisable at $0.80 per common share and will expire 10 years from the grant date. The options are subject to the terms of the company’s equity incentive plan, the applicable option agreement, and the requirements of the TSX Venture Exchange.
Seegnal aims to solve one of the top causes of death and injuries in the modern world, Adverse Drug Effects (ADEs). The company’s Clinical Decision Support system introduces a patient-centric standard. Seegnal’s SaaS technology exclusively integrates, at the point of care, patient-specific data such as genetics, lab results, ECG, smoking status, allergies, food interactions, gender, age, and the effects of concomitant medications, while reducing the current alert load for clinicians by over 90%.
Clinicians using Seegnal eHealth complete their prescription workflow with limited interruption, saving time and fatigue. Patients enjoy more tailored medication and improved safety, leading to better quality of life, with precision alerts reaching up to 98% accuracy. Institutions have reported reductions in admissions, medication consumption, and time savings in prescription renewals.
Seegnal eHealth is marketing its SaaS-based platform in Israel, the UAE, the United Kingdom, the United States, and Poland. The Ministry of Health in Israel recently adopted Seegnal’s patient-specific standard as the new standard in governmental hospitals. The platform is currently a standard of care system for over 10,000 clinicians in Israel, used daily for prescribing medications.
Contact:
Seegnal Inc.
Source: Seegnal Inc.
